Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting beta(2)-adrenoceptor agonists

被引:0
|
作者
Linden, A
Rabe, KF
Lofdahl, CG
机构
[1] GOTHENBURG UNIV, SAHLGRENS HOSP, DIV PULM MED, S-41345 GOTHENBURG, SWEDEN
[2] KRANKENHAUS GROSSHANSDORF, LANDESVERSICHERUNGANSTALT HAMBURG, ZENTRUM PNEUMOL & THORAXCHIRURG, D-22927 GROSSHANSDORF, GERMANY
关键词
airway smooth-muscle relaxation; beta(2)-adrenoceptor agonists; bronchodilator; duration of action; exosite; formoterol; microkinetic diffusion; salmeterol; BETA-ADRENOCEPTOR AGONISTS; AIRWAY SMOOTH-MUSCLE; GUINEA-PIG TRACHEA; BETA-2-ADRENOCEPTOR AGONIST; FUNCTIONAL ANTAGONISM; SALBUTAMOL; RELEASE; BAMBUTEROL; INVITRO; ASTHMA;
D O I
暂无
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The mechanisms behind the long duration of bronchodilating action of the beta(2)-adrenoceptor agonists formoterol and salmeterol are only partially understood, This review compares pharmacological characteristics of long-acting versus short-acting beta(2)-adrenoceptor agonists in human and animal airways. Based upon the reviewed evidence, it is concluded that for beta(2)-adrenoceptor agonists, long duration of action may depend upon several factors, Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta(2)-adrenoceptor. Of these factors, lipophilicity may prove to be one of the most important ones by determining the amount of drug entering into the cell membrane in the vicinity of the beta(2)-adrenoceptor. However, the receptor affinity, maximal relaxant effect (efficacy or intrinsic activity), potency, and receptor selectivity may also be of importance in determining how much beta(2)-adrenoceptor agonist must remain at the receptor for sustained action.
引用
收藏
页码:1 / 22
页数:22
相关论文
共 50 条
  • [21] Overuse of Short-Acting Beta-2 Agonists (SABAs) in Elite Athletes: Hypotheses to Explain It
    Vertadier, Nicolas
    Trzepizur, Wojciech
    Faure, Sebastien
    SPORTS, 2022, 10 (03)
  • [22] ANTIINFLAMMATORY EFFECTS OF A SHORT-ACTING AND A LONG-ACTING BETA(2)-ADRENOCEPTOR AGONIST IN GUINEA-PIG SKIN
    TEIXEIRA, MM
    WILLIAMS, TJ
    HELLEWELL, PG
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 272 (2-3) : 185 - 193
  • [23] Over-the-counter use of short-acting beta-2 agonists: a systematic review
    Zhe Chi Loh
    Rabia Hussain
    Siew Chin Ong
    Bandana Saini
    Jaya Muneswarao
    Anees ur-Rehman
    Zaheer-Ud-Din Babar
    Journal of Pharmaceutical Policy and Practice, 16
  • [24] Over-the-counter use of short-acting beta-2 agonists: a systematic review
    Loh, Zhe Chi
    Hussain, Rabia
    Ong, Siew Chin
    Saini, Bandana
    Muneswarao, Jaya
    ur-Rehman, Anees
    Babar, Zaheer-Ud-Din
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [25] Ending the reign of short-acting β2-agonists in Australia?
    Price, David
    Jenkins, Christine
    Hancock, Kerry
    Vella, Rebecca
    Heraud, Florian
    Le Cheng, Porsche
    Murray, Ruth
    Bosnic-Anticevich, Sinthia
    Botini, Fabio
    Carter, Victoria
    Catanzariti, Angelina
    Doan, Joe
    Kichkin, Ata
    Thao Le
    Le Lievre, Chantal
    Lau, Chi Ming
    Novic, Dominique
    Pakos, John
    Ranasinghe, Kanchanamala
    Roussos, Alex
    RESPIROLOGY, 2023, 28 : 19 - 20
  • [26] Paradoxical asthma hazard of short-acting β2-agonists
    Seed, M. J.
    Agius, R. M.
    ALLERGY, 2008, 63 (02) : 241 - 241
  • [27] Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting β2-agonists
    Murray, J
    Rosenthal, R
    Somerville, L
    Blake, K
    House, K
    Baitinger, L
    VanderMeer, A
    Dorinsky, P
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2004, 93 (04) : 351 - 359
  • [28] Exosites: Their current status, and their relevance to the duration of action of long-acting beta(2)-adrenoceptor agonists
    Coleman, RA
    Johnson, M
    Nials, AT
    Vardey, CJ
    TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (09) : 324 - 330
  • [29] Vasomolol: An ultra short-acting and vasorelaxant vanilloid type beta(1)-adrenoceptor antagonist
    Lin, YT
    Wu, BN
    Wu, JR
    Lo, YC
    Chen, LC
    Chen, IJ
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (01) : 149 - 157
  • [30] SALMETEROL, A NOVEL, LONG-ACTING BETA-2-ADRENOCEPTOR AGONIST - CHARACTERIZATION OF PHARMACOLOGICAL ACTIVITY INVITRO AND INVIVO
    BALL, DI
    BRITTAIN, RT
    COLEMAN, RA
    DENYER, LH
    JACK, D
    JOHNSON, M
    LUNTS, LHC
    NIALS, AT
    SHELDRICK, KE
    SKIDMORE, IF
    BRITISH JOURNAL OF PHARMACOLOGY, 1991, 104 (03) : 665 - 671